Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
about
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerCervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choicesAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.Human papillomavirus and cervical cancer: biomarkers for improved prevention effortsThe clinical implementation of primary HPV screening.Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population.Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural ChinaNon-inferiority and superiority tests for partially matched data when a constraint is placed on the number of new tests.Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) studyQuality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study.Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening.New HPV16 viral biomarkers to understand the progression of cervical lesions towards cancer.Impact of improved classification on the association of human papillomavirus with cervical precancer.Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men.Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.Cervical human papillomavirus prevalence and genotype distribution among hybrid capture 2 positive women 15 to 64 years of age in the Gurage zone, rural EthiopiaImportance of HPV Genotyping for the Screening, Therapy and Management of Cervical NeoplasiasDiagnostic efficacy of computer extracted image features in optical coherence tomography of the precancerous cervixGlobal proficiency study of human papillomavirus genotyping.[Molecular diagnosis of HPV infections].Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancerHPV testing by cobas HPV test in a population from Catalonia.Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.Clinical application of DNA ploidy to cervical cancer screening: A review.From Human Papillomavirus (HPV) Detection to Cervical Cancer Prevention in Clinical Practice.Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and meta-analysis.Comparison of Hybribio GenoArray and Roche human papillomavirus (HPV) linear array for HPV genotyping in anal swab samplesHuman papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic reviewClinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.The indicating FTA elute cartridge a solid sample carrier to detect high-risk HPV and high-grade cervical lesions.Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia.Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study.Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes
P2860
Q24607403-DEB91D29-6BF5-47B8-8706-DC18587EB2FDQ26775085-ED33A2D7-85F6-4B54-B9BE-9E2E6735926BQ26828840-6EBDFC3B-146A-4415-AB7B-ADB4BCA47EB2Q27023127-8C702220-27E5-4841-ADD5-C0CEAC4B8491Q30238954-FA978C27-A971-4035-96E2-97D0443C5386Q30301116-2325670A-6425-4991-B6F6-C1CDC9E133B1Q30409312-D617B875-654D-40D6-BE46-E110A13F0BA0Q30579744-8AC5340E-B790-4068-8CEE-6D2460926911Q30651813-C584B44C-D266-4755-BF0B-37801046DC55Q30829696-F5F6DD28-02E0-44AA-9BC5-2CCDD03204B0Q33704719-C0D52BB6-6B21-4F23-89DC-0B86A46ECF5FQ33833622-C0989B4A-17A2-4517-ABF4-960C2BE7EF95Q33883581-C60702B9-FA88-495E-B446-5AFA70910417Q33933176-D96FA79D-88D3-4396-BA04-5BA62E5C13F6Q34046296-6BFB8617-1015-48B2-B6F1-75564B765376Q34058759-1FA69595-85FE-402F-91D6-781EE62F3101Q34250191-99A879B0-83F2-4F8A-BC15-3C48446AEE44Q34340212-BBD00F47-4831-49A3-9D60-5D9F3C644DD9Q34432811-11C2F586-71FD-439F-A3B9-5A3F208C6AA6Q34473992-452A6BF7-04FE-428A-BC00-5AEC0ACFE5E4Q34489632-B3459202-5C39-4D8D-ACCE-1F04F31568A9Q34543310-F3166127-1257-40FB-82E9-00AA33AC7C8EQ34596772-C1E2B129-2EC4-4AE0-B1AB-78ED60E7E6D2Q34618650-8FF864FF-4A9C-4683-85B4-ADD6C965A0ACQ34637954-E8A45E45-880A-4DAF-A0AF-8F86A6DE0281Q34657755-41F81F7E-281B-491C-9FD8-6034884EE254Q34774870-53E4D088-FCDB-4A7D-B7F5-65B5B89FFA11Q34913072-55331E0C-F6D6-42A6-BB8C-499477EF47FBQ34983076-4E58ADD2-8AC9-4B0F-A7D7-C784450EEF45Q34997580-72B0BDD5-1C6D-4EAC-8148-0D705520E052Q35036033-6E500CE6-8CFB-4ED9-A58A-E1BDF5ECA00EQ35036313-67427EA4-C146-452E-B0FF-C11BFDB76CFCQ35066533-1347198E-0709-4D62-9162-DD2C8D88C47DQ35066980-AA50C045-1EA3-4C0E-9B77-92D42FCCE7E0Q35069896-40FD5EEA-2A84-4969-9CD9-1C83085CFB44Q35124750-F62E7D21-F70D-4B7A-ADC7-0BE5D7CFAFC3Q35139772-1F7FA04D-68D2-421C-BFC8-D5F3ED51CBC7Q35203306-6BB8A5BC-CD93-47BB-AC01-3D8EB7A7C515Q35212627-EFAC00B6-58B0-4329-8563-5AC8C045E0E3Q35273321-9218363E-BA0B-4A44-A519-C4FA714D6C5F
P2860
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Guidelines for human papilloma ...... g in women 30 years and older.
@en
Guidelines for human papilloma ...... g in women 30 years and older.
@nl
type
label
Guidelines for human papilloma ...... g in women 30 years and older.
@en
Guidelines for human papilloma ...... g in women 30 years and older.
@nl
prefLabel
Guidelines for human papilloma ...... g in women 30 years and older.
@en
Guidelines for human papilloma ...... g in women 30 years and older.
@nl
P2093
P2860
P356
P1476
Guidelines for human papilloma ...... g in women 30 years and older.
@en
P2093
Albertus T Hesselink
Chris J L M Meijer
Daniëlle A M Heideman
F Xavier Bosch
Guglielmo Ronco
Jack Cuzick
Johannes Berkhof
Marc Arbyn
Peter J F Snijders
Philip E Castle
P2860
P304
P356
10.1002/IJC.24010
P577
2009-02-01T00:00:00Z